Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Philipp Spatz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University Würzburg, Am Hubland, D-97074 Würzburg…. Hauptthemen laut MEDLINE: Butyrylcholinesterase, Alzheimer Disease. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Elitenetzwerk Bayern, Deutsche Forschungsgemeinschaft, Fonds Wetenschappelijk Onderzoek.
Themen: Demenz
Abstract (Originalsprache)
We present the synthesis and characterization of merged human butyrylcholinesterase (hBChE) inhibitor/cannabinoid receptor 2 (hCB2R) ligands for the treatment of neurodegeneration. In total, 15 benzimidazole carbamates were synthesized and tested for their inhibition of human cholinesterases, also with regard to their pseudoirreversible binding mode and affinity toward both cannabinoid receptors in radioligand binding studies. After evaluation in a calcium mobilization assay as well as a β-arrestin 2 (βarr2) recruitment assay, two compounds with balanced activities on both targets were tested for their immunomodulatory effect on microglia activation and regarding their pharmacokinetic properties and blood-brain barrier penetration. Compound 15d, containing a dimethyl carbamate motif, was further evaluated in vivo, showing prevention of Aβ25-35-induced learning impairments in a pharmacological mouse model of Alzheimer's disease for both short- and long-term memory responses. Additional combination studies proved a synergic effect of BChE inhibition and CB2R activation in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University Würzburg, Am Hubland, D-97074 Würzburg, Germany.
- Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
- MMDN, University of Montpellier, EPHE, INSERM, 34095 Montpellier, France.
- Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
ORCID-Profile: Sophie A M Steinmüller, Anna Tutov, Christophe P Stove, Barbara Monti, Tangui Maurice, Michael Decker
Förderung
- Elitenetzwerk Bayern
- Deutsche Forschungsgemeinschaft
- Fonds Wetenschappelijk Onderzoek
- Bayerisch-Franz?sisches Hochschulzentrum
Zitieren
APA
Spatz, P., Steinmüller, S. A. M., Tutov, A., Poeta, E., Morilleau, A., Carles, A., Deventer, M. H., Hofmann, J., Stove, C. P., Monti, B., Maurice, T., & Decker, M. (2023). Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00541
Vancouver
Spatz P, Steinmüller SAM, Tutov A, Poeta E, Morilleau A, Carles A, et al. Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00541
BibTeX
@article{Spatz2023,
author = {Spatz, Philipp and Steinmüller, Sophie A M and Tutov, Anna and Poeta, Eleonora and Morilleau, Axelle and Carles, Allison and Deventer, Marie H and Hofmann, Julian and Stove, Christophe P and Monti, Barbara and Maurice, Tangui and Decker, Michael},
title = {Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00541}
}
EUVIMED